Steven Demetropoulos, MD
General Practice · Ocean Springs, MSNPI 1932259546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by GSK at 28.6% of the total. Reporting peaked in 2021 at $1,503 and has fallen 67.8% since, to $484 in 2025. Among general practice clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$915
- AbbVie$679
- Lilly USA, LLC$618
- Novo Nordisk$466
- Gilead$291
- plus $1K from 28 others
What the payments were for
- Food & beverage$6,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 151 | $1,764 |
| AstraZeneca | 54 | $915 |
| AbbVie(2 entities) | 41 | $679 |
| Lilly USA, LLC | 39 | $618 |
| Novo Nordisk | 35 | $466 |
| Gilead | 24 | $291 |
| Astellas Pharma US Inc | 12 | $194 |
| Pfizer | 8 | $125 |
| Johnson & Johnson(2 entities) | 8 | $118 |
| Boehringer Ingelheim | 7 | $117 |
| Amgen(2 entities) | 6 | $98 |
| Biohaven Pharmaceuticals, Inc. | 6 | $95 |
| Abbott | 5 | $88 |
| Renalytix AI, Inc. | 4 | $65 |
| Averitas Pharma Inc. | 3 | $60 |
| Mylan Specialty L.p. | 4 | $57 |
| Merck | 4 | $51 |
| Exact Sciences | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Bayer | 2 | $28 |
| Genentech USA, Inc. | 2 | $26 |
| Novartis | 2 | $24 |
| Viiv Healthcare Company | 1 | $23 |
| Medtronic | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$6,176 in reported general payments places this provider in the 95th percentile of 674 general practice providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,686 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,806 |
| Fluticasone Propionate | 176 | $1,858 |
| Doxycycline Hyclate | 199 | $1,599 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 90 | $1,010 |
| Methylprednisolone | 146 | $895 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $891 |
| CefuroximeCefuroxime Axetil | 38 | $743 |
| Amoxicillin | 76 | $383 |
| Losartan Potassium | 42 | $305 |
| Mupirocin | 35 | $285 |
| Oseltamivir Phosphate | 11 | $283 |
| Ondansetron OdtOndansetron | 26 | $270 |
| Azithromycin | 43 | $247 |
| ValacyclovirValacyclovir Hcl | 21 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,764 | $14,68623 claims |
| AstraZenecaBreztri Aerosphere | $915 | $6,80611 claims |
| PfizerPaxlovid | $125 | $031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 general practice providers in Mississippi.
Other general practice in Ocean Springs
- Tyler McCabeOcean Springs$3K
- Delphine ShannonGulfport$341K
- Chris GriffinRipley$13K
- William McClendonPascagoula$10K
- Erin GreenBrandon$10K
- Jason OlaivarGulfport$10K
- Jessica PerkinsNew Albany$9K
- Andrew HarrisJackson$8K
- Michael AnthonyStarkville$7K
- Katie WassonRidgeland$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.